Changes in E2F binding after phenylbutyrate-induced differentiation of Caco-2 colon cancer cells

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2951-2950

  Wang, Qing Mei ^a   Feinman, Rena ^a   Kashanchi, Fatah ^a   Houghton, Jean Marie ^a   Studzinski, George P ^a   Harrison, Lawrence E ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b University of Medicine and Dentistry of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE 2; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL STRAIN CACO 2; COLON CANCER; ENZYME ACTIVITY; GENE INACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ALKALINE PHOSPHATASE; CACO-2 CELLS; CARRIER PROTEINS; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; G1 PHASE; HUMANS; KINETICS; MICROTUBULE-ASSOCIATED PROTEINS; PHENYLBUTYRATES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; S PHASE; TIME FACTORS; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0005686626     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000.
2. Darzynkiewicz, Z., Traganos, F., Xue, S., and Melamed, M. Effect of n-butyrate on cell cycle progression and in situ chromatin structure of L1210 cells. Exp. Cell Res., 136: 279-293, 1981.
3. Barnard, J., and Warwick, G. Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ., 4: 495-501, 1994.
4. cdc2 activity. Proc. Soc. Exp. Biol. Med., 222: 150-156, 1999.
5. Brusilow, S. W., Danney, M., Waber, L. J., Batshaw, M., Burton, B., Levitsky, L., Roth, K., McKeethren, C., and Ward, J. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N. Engl. J. Med., 310: 1630-1634, 1984.
6. Liu, L., Shack, S., Stetler-Stevenson, W., Hudgins, W., and Samid, D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Invest. Dermatol., 10: 335-340, 1994.
7. Gore, S., Samid, D., and Weng, L. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res., 3: 1755-1762, 1997.
8. Shack, S., Miller, A., Liu, L., Prasanna, P., Thibault, A., and Samid, D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin. Cancer Res., 2: 865-872, 1996.
9. Carducci, M. A., Nelson, J. B., Chan-Tack, K. M., Ayyagari, S. R., Sweatt, W. H., Campbell, P. A., Nelson, W. G., and Simons, J. W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996.
10. Studzinski, G. P., and Harrison, L. E. Differentiation-related changes in the cell cycle traverse. In: K. W. Jeon (ed.), International Review of Cytology, pp. 1-41. San Diego, CA: Academic Press, 1999.
11. Warrell, R. P., He, L., Richon, V., Calleja, E., and Pandolfi, P. Therapeutic targeting of transcription in acute promyelocylic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., 90: 1621-1625, 1998.
12. Harrison, L. E., Wojciechowicz, D. C., Brennan, M. F., and Paty, P. B. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery, 124: 541-550, 1998.
13. 1 arrest and apoptosis in myeloid leukemia cells: structure-functional analysis. Leukemia (Baltimore), 13: 1243-1253, 1999.
14. Melichior, S. W., Brown, L. G., Figg, W. D., Quinn, J. E., Santucci, R. A., Brunner, J., Thuroff, J. W., Lange, P. H., and Vessalla, R. L. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. Int. J. Oncol., 14: 501-508, 1999.
15. Huang, Y., and Waxman, S. Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cell by phenylbutyrate. Clin. Cancer Res., 4: 2503-2509, 1998.
16. Ink4a is associated with, but not sufficient for, induction of squamous differentiation. J. Cell Sci., 111: 1185-1196, 1998.
17. 3 in HL60 cells. Cancer Res., 56; 264-267, 1996.
18. Grana, X., Garriga, J., and Mayol, X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene, 17: 3365-3383, 1998.
19. Richon, V. M., and Venta-Perez, G. Changes in E2F DNA-binding activity during induced erythroid differentiation. Cell Growth Differ., 7: 31-42, 1996.
20. Garriga, J., Limon, A., Mayol, X., Rane, S. G., Albrecht, J. H., Reddy, E. P., Andres, A., and Grana, X. Differential regulation of the retinoblastoma family of proteins during cell cycle proliferation and differentiation. Biochem. J., 333: 645-654, 1998.
21. Shin, E. K., Shin, A., Paulding, C., Schaffhausen, B., and Yee, A. S. Multiple change in E2F function and regulation occur upon muscle differentiation. Mol. Cell. Biol., 15: 2252-2262, 1995.
22. Kiess, M., Gill, R. M., and Hamel, P. A. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation. Cell Growth Differ., 6: 1287-1298, 1995.
23. Corbeil, H. B., Whyte, P., and Branton, P. E. Characterization of transcription factor E2F complexes during muscle and neuronal differentiation. Oncogene. 11: 909-920, 1995.
24. Smith, E. J., Leone, G., and Nevins, J. R. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ., 9: 297-303, 1999.
25. Zhu, L., van den Heuvel, S., Helin, K., Fattaey, A., Ewen, M., Livingston, D., Dyson, N., and Harlow, E. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev., 7: 1111-1125, 1993.
26. Zamanian, M., and La Thangue, N. B. Transcriptional repression by the Rb-related protein p107. Mol. Cell. Biol., 4: 389-396, 1993.
27. Pineau, T., Hudgins, W. R., Liu, L., Chen, L. C., Sher, T., Gonzalez, F. J., and Samid, D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol., 52: 659-667, 1996.
28. Altiok, S., Xu, M., and Spiegelman, B. M. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev., 11: 1987-1998, 1997.
29. Lea, M. A., and Tulsyan, N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. Anticancer Res., 15: 879-884, 1995.
30. Magnaghi-Jaulin, L., Groisman, R., Naguibneva, I., Robin, P., Loralin, S., LeVillain, J. P., Troalen, F., Trouche, D., and Harel-Bellan, A. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (Lond.), 391: 601-605, 1998.
31. Auwerx, J. PPARγ, the ultimate thrifty gene. Diabetologia, 42: 1033-1049, 1999.